二价HPV疫苗单剂保护作用的证据——哥斯达黎加HPV疫苗试验回顾与未来研究
哥斯达黎加疫苗试验(CVT)是一项III期随机临床试验,最初数据显示单剂HPV疫苗可提供持久保护以对抗HPV感染。尽管设计为三剂接种,20%女性未完成三剂方案。2011年报告单剂二价HPV疫苗在持续HPV感染终点上可能与三剂同样有效,此发现被PATRICIA试验独立证实。单剂后抗体水平虽低于三剂,但为自然感染的9倍,且至少7年内基本保持恒定。
要点
- CVT试验中20%女性未接受三剂方案,多因与接种无关的非自愿原因。
- 单剂二价HPV疫苗在持续HPV感染终点上可能与三剂同样有效。
- 单剂后抗体水平为自然感染的9倍,至少7年内基本恒定。
核心结论
- 单剂二价HPV疫苗可能提供与三剂相当的持久保护,但现有证据来自非随机亚组,需正式随机对照试验验证。
研究设计与样本
- 哥斯达黎加疫苗试验(CVT)为III期随机临床试验,设计为所有参与者接种三剂HPV疫苗或对照疫苗;20%女性未接受三剂方案。
主要发现
- 单剂二价HPV疫苗在试验前四年累积的持续HPV感染终点上可能与三剂同样有效,该发现被GSK赞助的PATRICIA试验独立证实。
- 单剂后抗体水平虽低于三剂诱发的水平,但为自然感染诱发水平的9倍,且至少7年内基本保持恒定。
局限性
- CVT和PATRICIA试验中接受单剂二价HPV疫苗的受试者组样本量小,且非随机选择,也未对接种剂次设盲。
- 单剂保护作用的非随机发现需正式随机对照试验进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Costa Rica Vaccine Trial (CVT), a phase III randomized clinical trial, provided the initial data that one dose of the HPV vaccine could provide durable protection against HPV infection. Although the study design was to administer all participants three doses of HPV or control vaccine, 20% of women did not receive the three-dose regimens, mostly due to involuntary reasons unrelated to vaccination. In 2011, we reported that a single dose of the bivalent HPV vaccine could be as efficacious as three doses of the vaccine using the endpoint of persistent HPV infection accumulated over the first four years of the trial; findings independently confirmed in the GSK-sponsored PATRICIA trial. Antibody levels after one dose, although lower than levels elicited by three doses, were 9-times higher than levels elicited by natural infection. Importantly, levels remained essentially constant over at least seven years, suggesting that the observed protection provided by a single dose might be durable. Much work has been done to assure these non-randomized findings are valid. Yet, the group of recipients who received one dose of the bivalent HPV vaccine in the CVT and PATRICIA trials was small and not randomly selected nor blinded to the number of doses received. The next phase of research is to conduct a formal randomized, controlled trial to evaluate the protection afforded by a single dose of HPV vaccine. Complementary studies are in progress to bridge our findings to other populations, and to further document the long-term durability of antibody response following a single dose.
引用
- Kreimer AR, Herrero R, Sampson JN, et al. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine. 2018. PMID: 29366703. doi:10.1016/j.vaccine.2017.12.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。